NBIX Financial Facts
Income (loss) from operations: -38.44MTotal revenues: 0
See Full Income Statement
Current portion of deferred gain on sale of real estate: 3.5M
Deferred revenues: 10.23M
See Full Balance Sheet
Neurocrine Biosciences Inc. (NBIX) Earnings
|
Expand Research on NBIX
| Next EPS Date | 7/30/26 *Est. | EPS Growth Rate | -100.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +25.1% | Revenue Growth Rate | -100.0% *Last Qtr. |
| Average % Move 1-Wk after EPS | -2.9% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
5/6/26  |
Q126 | N/A | $1.15 | N/A | N/A | $770.29M | = | N/A | N/A | ||
| 2/11/26 | Q425 | $1.88 | $1.86 | +$0.02 | $805.5M | $802.45M | = |  | | Details | |
| 10/28/25 | Q325 | $2.17 | $1.59 | +$0.58 | $794.9M | $748.62M | = | | | Details | |
| 7/30/25 | Q225 | $1.65 | $0.96 | +$0.69 | $687.5M | $653.32M | = | | | Details | |
| 5/5/25 | Q125 | $0.70 | $0.77 | -$0.07 | $572.6M | $593.71M | = | | | Details | |
| 2/6/25 | Q424 | $1.69 | $1.57 | +$0.12 | $627.7M | $630.01M | = | | | Details | |
| 10/30/24 | Q324 | $1.81 | $1.52 | +$0.29 | $622.1M | $600.97M | = | | | Details | |
| 8/1/24 | Q224 | $1.63 | $1.13 | +$0.50 | $580M | $547.1M | = | | | Details |
